BPC-157: The Body Protection Compound Explained

What is BPC-157?

BPC-157 stands for Body Protection Compound 157. It is a synthetic peptide consisting of 15 amino acids, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a larger protective protein found naturally in human gastric juice, which is why researchers sometimes refer to it as a "gastric pentadecapeptide."

The peptide was first described and characterized in the early 1990s by Predrag Sikiric, a professor of pharmacology at the University of Zagreb School of Medicine, along with his longtime collaborator Sven Seiwerth and their research group. Their initial publications focused on the peptide's cytoprotective effects in the gastrointestinal tract, and the body of work has expanded over three decades into musculoskeletal, cardiovascular, and neurological injury models.

One of BPC-157's most unusual properties is its stability in stomach acid. Most peptides are rapidly degraded by the hydrochloric acid and digestive enzymes in the stomach, which is exactly why drugs like insulin must be injected rather than swallowed. BPC-157, because its parent protein evolved to function in gastric juice, survives this environment intact. This stability is what makes the oral-versus-injectable debate relevant for this particular peptide, a topic covered separately in our oral vs injectable peptides article.

How BPC-157 is thought to work

The mechanism researchers have focused on most is angiogenesis, the formation of new blood vessels. When tissue is injured, especially in areas with poor blood supply like tendons and ligaments, the rate-limiting step in healing is often getting enough oxygen, nutrients, and repair cells to the damage site. New blood vessels solve this bottleneck.

In laboratory and animal studies, BPC-157 appears to activate several interconnected signaling pathways. It has been shown to upregulate vascular endothelial growth factor (VEGF), a key driver of new vessel formation. It modulates nitric oxide pathways, which regulate blood vessel dilation and blood flow to injured areas. And it has been observed to increase growth hormone receptor expression on tendon fibroblasts, the cells responsible for producing collagen in tendons (Chang et al., Molecules, 2014, PMC6271067). This last finding is particularly relevant to surgical recovery because it suggests BPC-157 may help tendon cells respond more effectively to the body's own growth hormone, rather than introducing an external signal.

Beyond angiogenesis, BPC-157 has demonstrated anti-inflammatory effects in animal models, appearing to reduce pro-inflammatory cytokines like TNF-alpha and IL-6 while supporting the transition from destructive inflammation to productive repair. It also appears to promote fibroblast proliferation, survival, and migration, all of which are critical during the proliferative phase of wound healing. For more on the inflammation angle, see our article on peptides and post-surgical inflammation.

What the animal research shows

The preclinical evidence for BPC-157 is broad and remarkably consistent. Across dozens of studies, primarily conducted in rat models, BPC-157 has accelerated healing of transected Achilles tendons with improved biomechanical strength at the repair site, enhanced ligament healing after surgical transection, improved muscle injury recovery, accelerated bone fracture consolidation, healed gastric and intestinal ulcers, and improved outcomes in surgical anastomosis models (where two pieces of tissue are surgically joined together).

In tendon models specifically, BPC-157-treated animals showed faster and more organized collagen deposition, better tensile strength at the repair site, and improved functional outcomes compared to controls. The 2025 systematic review by Vasireddi et al. at University Hospitals Cleveland Medical Center identified 35 preclinical studies meeting inclusion criteria across PubMed, Cochrane, and Embase databases (PMID 40756949). The review noted that BPC-157 enhanced growth hormone receptor expression and several pathways involved in cell growth and angiogenesis while reducing inflammatory cytokines.

The breadth of tissues that respond to BPC-157 in animal models is unusual for a single compound and is part of what makes it both interesting and difficult to fully characterize. The Zagreb group has described this as "pleiotropic cytoprotection," meaning the peptide appears to support cellular survival and repair across many tissue types simultaneously (Jozwiak et al., Pharmaceuticals, 2025, PMC11859134). For the orthopedic angle specifically, see our article on peptides and orthopedic surgery.

What about humans?

As of September 2026, published human research on BPC-157 remains extremely limited. The entire clinical evidence base consists of three small studies.

The first is a retrospective case series examining intra-articular BPC-157 injection for chronic knee pain. In this study, 7 of 12 patients reported meaningful pain relief lasting more than six months after a single injection. There was no placebo control group, no randomization, and no blinding.

The second is a case series exploring BPC-157 for interstitial cystitis symptoms. The rationale was that BPC-157's demonstrated ability to restore damaged epithelium and reduce inflammation in animal gut models might translate to the bladder lining. Results were described as positive, but the study was small and uncontrolled.

The third, published in 2025 by Lee and Burgess, was a safety pilot involving two healthy adults who received intravenous BPC-157 infusions at doses up to 20 mg. The peptide was well tolerated with no adverse events and no clinically significant changes in cardiac, hepatic, renal, thyroid, or metabolic biomarkers. Pharmacokinetic analysis showed that plasma BPC-157 concentrations returned to baseline within 24 hours.

Across all three studies combined, only a few dozen people have received BPC-157 in any published clinical setting. A larger placebo-controlled trial for an inflammatory bowel condition was reportedly conducted years ago, but its full results were never published, a gap the field has not addressed.

The 2025 narrative review by the Current Reviews in Musculoskeletal Medicine team (PMID 40789979) explicitly noted that independent laboratory replication outside the Zagreb group has been limited. A PubMed search as of early 2025 found that over 80 percent of all BPC-157 publications list Sikiric or Seiwerth as first or senior author. Independent confirmation is starting to emerge, but the concentration of evidence within a single research group remains a legitimate scientific concern.

The honest takeaway

BPC-157 has an interesting scientific story backed by a large, consistent body of animal research and a plausible mechanism of action centered on angiogenesis and tissue repair signaling. What it lacks is the kind of rigorous, placebo-controlled, adequately powered human trial data that would move it from "promising preclinical candidate" to "proven therapy."

That does not mean it does not work in people. It means the evidence is not yet strong enough to know for certain, and anyone claiming otherwise is ahead of the data. Its regulatory status is covered in our safety and FDA article, and sourcing considerations are in our guide to finding quality peptides.